Month: March 2022

Pressure injuries are common among patients who experience extended exposure to pressure on a bony prominence or shear to areas of poor turgor, two factors that lead to constriction of a patient’s blood supply to the exposed area. A patient who is bedridden or has certain chronic conditions, such as diabetes,1 is more likely to develop a pressure injury. When mechanical force is imposed on the skin, it can result in poor blood flow and damage to the bone-muscle interface, thus making tissue sensitive and painful. For patients with limited mobility, this can be especially frustrating because they may not be able to adjust positions or medical equipment. If pressure injuries are left untreated or unnoticed, they can also become infected and even enter muscle and bone. Risk assessment tools are available to assess pressure injury risk and can work in tandem with practice standardization, thereby leading to effective treatment plans for practitioners and patients … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Lessons Learnt From a National Referral Hospital in Indonesia

 

Abstract
Background: Diabetic foot ulcer (DFU) is one of the most terrifying diabetic complications for patients, due to the high mortality rate and risk for amputation. During the COVID-19 pandemic, many diabetic patients limited their visits to the hospital, resulting in delays for treatment especially in emergency cases.

 

Objective: This study aimed to compare the characteristics of patients with DFU pre- and during COVID-19 pandemic period. Methods: This study was a retrospective cohort study using foot registry data. We compared our patients’ characteristics pre-COVID-19 pandemic period (1 March 2019-28 February 2020) and during COVID-19 pandemic period (1 March 2020-28 February 2021).

 

Results: Cohorts of 84 and 71 patients with DFU pre- and during COVID-19 pandemic period, respectively, were included in this study. High infection grade (66.7% vs 83.1%, P = .032), osteomyelitis event (72.6% vs 87.3%, P = .04), leukocyte count (15 565.0/μL vs 20 280.0/μL, P = .002), neutrophil-to-lymphocyte ratio (7.7 vs 12.1, P = .008), waiting time-to-surgery (39.0 h vs 78.5 h, P = .034), and number of major amputation (20.2% vs 39.4%, P = .014) were significantly higher during the COVID-19 pandemic period.

 

Conclusion: During the COVID-19 pandemic, patients with DFU had more severe infection, higher proportion of osteomyelitis, longer waiting time for getting surgical intervention, and higher incidence of major amputation.

 

Keywords: COVID-19; amputation; diabetic foot ulcer; infection; mortality; waiting time to surgery.
… from PubMed

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

A person formerly incarcerated at the Allegheny County Jail has filed a lawsuit against multiple members of the jail’s medical staff alleging that a lack of medical treatment in the facility led to the amputation of his leg … In 2011, McCray was shot in the spine, which caused him to lose one of his kidneys and develop a drop foot, which due to dragging of the foot and numbness, made him more susceptible to developing ulcers on his foot, the lawsuit said … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

86 year old female Ankle Wound – Pyoderma Gangrenosum After four years of treating using Santyl, honey, silver products, alginates, Aquacel Ag, Bactroban, sharp debridement, etc. Positive biopsy for PG, Autoimmune disease (lupus) common comorbidity associated with PG A home health, wound-care nurse treated 1.5 years Patient now self-treating Occasional visit to rheumatologist 40 mg of oral steroids Wound healed in only 5 months with Pure&Clean

RedDress, a Florida-based Israeli medical company is shipping revolutionary blood-clotting wound care systems to Ukraine to help with serious injuries and severe trauma wounds … RedDress began shipments of 400 of their ActiGraft systems this week to multiple hospitals in Ukraine to help treat civilian casualties as a result of the indiscriminate Russian attacks … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Kristin Fuller, MD
Mr. K. was a 37-year-old male who I saw in my clinic for uncontrolled type-2 diabetes. Every time he came in, his HbA1c and rapid glucose were off the charts. He had multiple hospital admissions for diabetic ketoacidosis, and already had two toes amputated due to severe peripheral arterial disease, a known diabetes complication … One day, a surgeon called to inform me that Mr. K. was in the hospital and would be undergoing a below-the-knee amputation (BKA) due to extremely poor circulation as a result of poor glycemic control. The surgeon initially tried to blame me for not having my patient on the proper diabetic regimen. I explained that I had consistently tried to work with Mr. K., and he was stubbornly non-compliant with his diet and insulin regimen … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Results from a Phase 3, Multicentre, Randomized, Active-controlled, Parallel-group Study

 

Diabetic foot ulcer (DFU), if untreated, accounts for lower-limb amputations affecting patients’ quality-of-life. Diperoxochloric acid (DPOCL) is known to heal DFU by its antibacterial and fibroblast stimulating activity. This was a phase 3, multicentre, randomized, double-blind, active-controlled, parallel-group study conducted to evaluate the efficacy and safety of topic solution of DPOCL compared with isotonic sodium chloride solution (ISCL). Adult patients with type 1 or 2 diabetes with random blood glucose levels of <250 mg/dL, with ≤ than three full-thickness foot ulcers were enrolled. Primary efficacy endpoint was complete wound closure and secondary was wound surface area. Adverse events were analyzed as safety endpoint. Of 311 enrolled patients, 289 were randomized … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Chronic Diabetic Foot Ulcers through Modifications of Infection, Angiogenesis, Macrophage Phenotype and Neutrophil Response

 

This work aimed to evaluate the adjuvant treatment to surgical debridement using topical applications of Lactiplantibacillus plantarum ATCC 10241 cultures in complicated diabetic foot ulcers as compared to diabetic foot ulcers receiving surgical wound debridement. A randomised controlled trial was performed involving 22 outpatients with complicated diabetic foot ulcers that either received surgical debridement (SuDe, n = 12) or surgical debridement plus topical applications of L. plantarum cultures (SuDe + Lp, n = 10) every week during a 12 week treatment period. Compared to patients receiving SuDe, patients treated with SuDe + Lp exhibited significantly increased fibroplasia and angiogenesis, as determined by Masson’s trichrome staining and the study of CD34 cells, α-smooth muscle actin to semi-quantify vascular area, number of vessels and endothelial cells. In addition, a promotion of the polarisation of macrophages from M1 (CD68) to M2 (CD163) phenotype was observed in SuDe + Lp patients with remarkable differences in the tissue localisation … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Dedee F. Murrell, MD, details the EASE trial findings presented at AAD 2022, and what the benefit of the novel topical gel may mean for patients with EB

 

A new phase 3 trial assessing a novel topical gel for the treatment of young patients with epidermolysis bullosa (EB) wounds show the birch bark-based product achieved nearly 50% heal of targeted wounds over 12 months … The interim EASE findings, presented in a late-breaking session at the American Academy of Dermatology (AAD) 2022 Annual Meeting in Boston, show birch triterpenes (Oleogel-S10) may provide a unique and broadly-applicable benefit for patients with rare, often deadly skin condition … In an interview with HCPLive at AAD 2022, study author Dedee F. Murrell, MD, director of dermatology at St. George Hospital, USNW, discussed the clinical history of Oleogel S-10 leading … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

chronic wounds proven by gold-standard trial

 

Comparative clinical trial shows significant improvement in wound closure and infection control based on treatment with the plasmajet kINPen® MED from neoplas med compared to best practice wound care – cost-effectiveness analysis proves high cost-savings by innovative technology

 

GREIFSWALD, Germany and FELDKIRCH, Austria, March 22, 2022 /PRNewswire/ — The results of a randomized controlled trial (RTC) may offer new opportunities for the approximately two million patients with chronic wounds solely in Germany: The innovative cold atmospheric plasmajet (CAP-jet) technology showed significantly more healing progress in chronic wounds in comparison to best practice (BP) modern wound care at two study centers. Within six weeks, 59 percent of all wounds healed completely under cold plasma treatment compared to only 5.1 percent in patients under BP therapy. Time to complete healing was also considerably shorter under CAP-jet treatment, and wound infections were overcome statistically significant more rapid. With a very good tolerability profile, an economic analysis of the study data also showed a cost saving of 65 percent for the dressing material alone compared to the BP group. The study data were recently published in the journal Nature Scientific Reports.

 

Acceleration of wound healing and wound closure proven

In the study conducted by Prim. Univ.-Professor Robert Strohal, head of the Department of Dermatology and Venereology at the Federal Academic Teaching Hospital Feldkirch, the cold plasma procedure of the Greifswald-based company neoplas med GmbH was scientifically examined in wound care. For this purpose, he compared treatment with the CAP-jet kINPen® MED at the Austrian Federal Academic Teaching Hospitals Feldkirch and Bregenz with current best practice treatment in 78 patients with infected and non-infected wounds. ‘This study was the first to investigate the exclusive effect of tissue accessible cold plasma on wound healing and infection control without the use of an additional standard therapy,’ said Prim. Univ.-Prof. Strohal.

 

After treatment with the CAP-jet, the proportion of healthy tissue increased significantly faster than under the BP treatment and the wounds under CAP-jet therapy also healed significantly faster. At the end of the study, the wound area in the CAP group had reduced by 94.7 percent compared to the baseline value, in the comparison group it was only 56.3 percent. CAP also proved superior in terms of infection control. In contrast to BP therapy, all wounds infected at the start of the study showed complete resolution of infection signs. In addition, the signs of infection disappeared significantly faster under cold plasmajet therapy.

 

Patients’ quality of life can improve

Ulrike Sailer, CEO of the company neoplas med GmbH in Greifswald/Germany, explained: ‘The Joint Federal Committee (Gemeinsamer Bundesausschuss, G-BA) as the central decision-making body of the German health care system already recognized last year the potential of cold plasma for the innovative treatment of chronic wounds at our request. Therefore, the G-BA decided to carry out an observational trial for testing with the aim of obtaining health insurance approval. The results of the clinical trial that now have been published clearly demonstrate the superiority of the CAP-jet kINPen® MED compared to BP wound care. These results provide further evidence for the high clinical relevance of the CAP-jet precision technology. At the same time, it represents important news for millions of people who suffer from chronic wounds for years.’

 

Chronic wounds are often associated with high morbidity and considerable impairments in everyday life as well as the patients’ psyche. Faster wound healing and thus a shorter therapy duration by using the plasmajet kINPen® MED can therefore significantly improve the patients’ quality of life. Furthermore, a lower burden by pain during treatment can be observed, and a reduced number of dressing changes can be assumed. Patients confirmed the very good tolerability and even described the treatment as pleasant in the majority of cases.

 

Significant advantage in treatment costs

A cost-effectiveness analysis based on the available study data showed that 21.4 percent fewer physician visits and 34.3 percent fewer dressing changes were necessary in the CAP-jet group compared to BP. The savings alone in dressing material resulted in a cost advantage for CAP-jet therapy of 64.7 percent compared to BP. Previously, average costs of 10,000 € per patient and year were assumed. Ulrike Sailer: ‘Thus, the cold plasmajet kINPen® MED offers not only a more efficient and tolerable technology, but also opens up the opportunity for significantly higher cost-effectiveness in the treatment of chronic wounds.’

 

Further information material can be found under the following link: https://1drv.ms/u/s!Aph6cOwNbPEJgQCIbClSETCZ_lal?e=BvkuGi

 

Background Information:

The study included 78 patients with wounds up to 10 x 20 cm in size and existing for at least 6 weeks. The patients were randomized in a 1:1 ratio into two groups and treated for the study duration of 6 weeks either with the CAP-jet kINPen® MED (30 seconds per cm2 wound area) or suitable wound dressings according to BP wound care. Only one wound per patient was evaluated.

 

With regard to the treatment regime, CAP-jet therapy was administered 3 times in the 1st week in the CAP group, 2 times in the 2nd week and once a week in the following observation period; furthermore, the wounds were covered with gauze and a secondary dressing. In contrast, the BP group was treated with a wound phase-adapted dressing; infected wounds were additionally cleaned with an antiseptic. In both groups, patients with venous ulcers received compression therapy. The primary endpoint of the study was the amount of granulation tissue at the end of the study. In addition, cold plasma effects on wound infection, wound area, healing time, wound pH and exudate volume (wound fluid) as well as local tolerability were investigated.

 

Improvement in wound infection: All 13 wounds infected at baseline in the CAP-jet group showed complete resolution of infection signs without the need for additional antiseptics. In contrast, 4 of the 18 wounds infected at baseline in the BP group showed no improvement despite the use of antiseptics. Furthermore, the signs of infection decreased significantly faster under CAP-jet therapy compared to BP therapy. These data confirm the previously published evidence on the good antimicrobial efficacy of CAP.

 

Cold plasma is a gas containing ionized atoms, ions and electrons that has been shown to disinfect wounds and activate the wound healing process. With its fine jet, the plasmajet kINPen® MED enables highly precise treatment in anatomically and pathologically challenging areas under visual control and without touching, which is not possible with other wound therapies.

 

About neoplas med GmbH

neoplas med GmbH was founded in 2009 as a spin-off of the Leibniz Institute for Plasma Science and Technology e. V. (INP) in Greifswald, Germany. Ulrike Sailer took over the position of managing director at the end of 2019. Based on the INP research into plasma medicine, the emerging company develops innovative products for medical applications. The first product developed on this basis is the CE-marked kINPen® MED atmospheric pressure plasmajet, the first internationally approved and marketed plasmajet for the treatment of chronic wounds and pathogen-induced skin disorders. It is the result of a long-lasting cooperation with the INP institute, the university hospital of Greifswald, Germany, the Charité hospital of Berlin, Germany, and various industrial partners. In July 2021, the Federal Joint Committee, as the central decision-making body in the self-governing health care system, decided on a trial study with the cold plasmajet procedure and thus took an important step towards reimbursement by the health insurance companies.

 

About kINPen® MED

The plasmajet kINPen® MED is the first atmospheric pressure plasmajet to receive CE approval for the treatment of chronic wounds and pathogen-induced skin disorders. The plasmajet applies a physical cold plasma with a temperature of < 40 degrees Celsius with pinpoint precision and without wound contact. Areas with an uneven profile, recesses or cavities can be reached easily and treated evenly. The noble gas argon used for the generation of the plasma provides a controlled atmosphere around the generated plasma beam, thus ensuring a consistent high treatment quality.

 

Press contact

Claudia Kerber
Phone: +49 3834 515 201
Mobile: +49 (0)162 23 770 70
claudia.kerber@neoplas-med.eu
neoplas med GmbH
Walther-Rathenau-Straße 49a, 17489 Greifswald, Germany

By Chase Doyle
If untreated or unsalvageable, the diabetic foot requires surgical interventions to address the risks to its viability. However, recent advancements in the field suggest that surgeons may not always have to sacrifice a limb to save a life.

During the 2021 virtual American College of Surgeons Clinical Congress, Lucas M. Ferrer, MD, described the use of endovascular venous arterialization for limb salvage, and William P. Robinson, MD, discussed the timing of foot amputation after revascularization … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Providing Renewed Hope for World’s Largest Diabetic Foot Ulcer Population

 

OCEANSIDE, Calif., March 23, 2022 /PRNewswire/ — Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today that is has received Chinese National Medical Products Administration (NMPA), commonly referred to as China FDA, approval for its unique cyclically pressurized Topical Wound Oxygen (TWO2) therapy. Making it the only advanced sustained wound healing therapeutic to have achieved such a designation and allowing the company to now commence marketing in China with its local partner.

 

China has the world’s largest Diabetic and resultingly Diabetic Foot Ulcer (DFU) population. The International Diabetes Federation estimates that 10.6% of the Chinese adult population now have diabetes that equates to 141 million people. This represents a 56%, or 50 million person, increase in the last 10 years alone.1 In China, the annual incidence of DFU and Amputation has recently been reported to be 8.1% and 5.1% respectively, representing a staggering 11.4 million ulcerations and 7.2 million preventable lower extremity amputations every year.2

 

AOTI’s globally patented TWO2 homecare therapy has been demonstrated in recently published high-quality Randomized Controlled Trial 3 and Real Word Evidence 4 studies to provide more durable complete DFU healing. Resulting in six-fold reductions in ulcer recurrence, with an unprecedented 88% reduction in hospitalizations and 71% reduction in lower extremity amputations seen over 12 months. Such sustained healing provides patients with renewed hope of limb preservation, while offering significant reductions in healthcare resource utilization with resultant health economic savings.

 

Professor Andrew Boulton, past-President of the European Association for the Study of Diabetes and Professor of Medicine at the University of Manchester, UK and University of Miami, USA, and Chairman of AOTI’s Scientific and Clinical Advisory Board, commented: “Diabetes is one of the fastest growing global health emergencies of the 21st century. It is a real game-changer to finally have clinically proven homecare therapeutics like TWO2 available that make meaningful impact in such critical outcomes as hospitalizations and amputations. Now that TWO2 therapy is authorized in China, the world’s largest diabetic foot ulcer population has a renewed hope for better outcomes.”

 

1 International Diabetes Federation. IDF Diabetes Atlas, 10th Edition. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org

 

2 Development and validation of a brief diabetic foot ulceration risk checklist among diabetic patients: a multicenter longitudinal study in China. Zhou, Q., Peng, M., Zhou, L. et al. Nature, Sci Rep 8, 962 (2018). https://doi.org/10.1038/s41598-018-19268-3

 

3 Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers; The TWO2 Study. Robert G. Frykberg et al, Diabetics Care 2020; 43:616-624. https://doi.org/10.2337/dc19-0476.

 

4 Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World Outcomes; Jessica Izhakoff Yellin, et al; Advances in Wound Care 2022; http://doi.org/10.1089/wound.2021.0118

 

About AOTI
AOTI is a privately-owned company based in Oceanside, California USA and Galway, Ireland that provides innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. Our patented non-invasive Topical Wound Oxygen (TWO2) homecare therapy is clinically proven to deliver Sustained Wound Healing that reduces both Amputations and Hospitalizations, So Life Can Get Back to Normal.

 

For more information see: www.aotinc.net
Dr. Mike Griffiths
CEO & President
332487@email4pr.com
(760) 672 1920
SOURCE AOTI Inc.

Janet Falade, PharmD Candidate, South College School of Pharmacy

 

The increased risk of having type 2 diabetes (T2D) and cardiovascular disease (CVD) has been a significant concern in the health care sector worldwide. Also, it has been regularly reported by the World Health Organization (WHO) that cardiovascular diseases (CVDs) and diabetes mellitus are part of the ten major leading causes of death globally. Some changes, such as increased blood pressure, cholesterol, and blood sugar level, are usually apparent before the onset of these diseases. Therefore, early detection of individuals at increased risk of having this disease is essential in preventing the disease Incidence. Furthermore, these diseases can influence specific measures like lifestyle changes such as healthy diet and exercise. In addition, machine learning models can help predict the risk of having T2D and CVD. Other factors such as lipid level and blood sugar levels, particularly evaluation of gene variations, protein complements, and metabolome, which includes lipidome, may aid in identifying physiopathology pathways that might be … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Debridement is the process of removing nonviable tissue and foreign objects (such as glass or shrapnel) from a wound bed to help the wound heal.1 Decaying tissue can trap bacteria and lead to a harmful infection such as gangrene, which is the death of body tissue resulting from a lack of appropriate blood flow or in response to a severe bacterial infection.2 Debridement is thus critical to effective wound management … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Antimicrobial Action, and in vivo Effect for Enhancing Wound Healing in Diabetic Rats

May Almukainzi, Thanaa A El-Masry, Walaa A Negm, Engy Elekhnawy, Asmaa Saleh, Ahmed E Sayed, Mohamed A Khattab, Dalia H Abdelkader

Download full article (PDF)

Purpose: Gentiopicroside (GPS), an adequate bioactive candidate, has a promising approach for enhancing wound healing due to its antioxidant and antimicrobial properties. Its poor aqueous solubility negatively affects oral absorption accompanied by low bioavailability due to intestinal/hepatic first-pass metabolism. Our aim in this study is to fabricate GPS into appropriate nanocarriers (PLGA nanospheres, NSs) to enhance its solubility and hence its oral absorption would be improved.

 

 

Methods: Normal and ODS silica gel together with Sephadex LH20 column used for isolation of GPS from Gentiana lutea roots. Crude GPS would be further processed for nanospheres fabrication using a single o/w emulsion solvent evaporation technique followed by in vitro optimization study to examine the effect of two formulation variables: polymer (PLGA) and stabilizer (PVA) concentrations on the physical characterizations of prepared NSs. Possible GPS-PLGA chemical and physical interactions have been analyzed using Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC). The optimum GPS-PLGA NSs have been chosen for antimicrobial study to investigate its inhibitory action on Staphylococcus aureus compared with unloaded GPS NSs. Also, a well-designed in vivo study on streptozotocin-induced diabetic rats has been performed to examine the wound healing effect of GPS-PLGA NSs followed by histological examination of wound incisions at different day intervals throughout the study.

 

 

Results: The optimum GPS PLGA NSs (F5) with well-controlled particle size (250.10± 07.86 nm), relative high entrapment efficiency (83.35± 5.71), and the highest % cumulative release (85.79± 8.74) have increased the antimicrobial activity as it exhibited a higher inhibitory effect on bacterial growth than free GPS. F5 showed a greater enhancing impact on wound healing and a significant stimulating effect on the synthesis of collagen fibers compared with free GPS.

 

Conclusion: These findings demonstrate that loading GPS into PLGA NSs is considered a promising strategy ensuring optimum GPS delivery for potential management of wounds … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

North Texas researchers hope their development will help ward off diabetic foot ulcers, which can lead to amputation.
Research scientists at The University of Texas at Arlington have developed footwear technology that may prevent the development of diabetic foot ulcers … People with diabetic neuropathy deal with numbness in their legs and feet and are often unable to detect and respond to stress-related pain by adjusting their foot loading … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

by Richard Payerchin
Work-life balance is the most important factor for new physicians choosing their first jobs – possibly as a result of dealing with stresses brought on by COVID-19, according to a new survey … The responses confirmed and surpassed a similar finding from a study of 2018, according to health staffing consultant CHG Healthcare. The company announced the survey from its CompHealth division, which surveyed 145 physicians who had been out of residency for two to three years … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

TAMPA, Fla., March 16, 2022 /PRNewswire/ — Leading wound care management and clinical services provider, WoundGenex, today announced a strategic partnership with MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX”), a transformational placental biologics company, to launch an exclusive version of WoundGenex’s Premier Graft Program to its clients across the country, providing clinicians access to industry-leading allograft products through a convenient purchasing option.

 

WoundGenex Partners with MIMEDX to Launch the first-of-its-kind Premier Graft Program.
The partnership adds the portfolio of MIMEDX advanced wound care products to the list of treatment options available to clinicians who rely on WoundGenex’s expertise in clinical documentation requirements, wound care revenue cycle, and reimbursement policies. Premier Graft Program members tap into group purchasing power that allows WoundGenex to facilitate product ordering at no upfront cost to the provider or organization. WoundGenex Program Liaisons work with providers and billing specialists to help streamline the entire process, including proper utilization of products, documentation of medical necessity, coding, and coding education, and more. A first-of-its-kind program, no payment is due from the ordering providers until reimbursement is realized on the product.

 

MIMEDX is a leading provider of placental allografts in the Cellular Tissue Products/Skin Substitute segment of the advanced wound care category. MIMEDX’s flagship advanced wound care product, EPIFIX®, is covered by 100% of national commercial payors for the treatment of diabetic foot ulcers, totaling over 300 million covered lives.

 

“WoundGenex is thrilled to be able to partner with MIMEDX to introduce a meaningful solution to providers to maximize clinical and reimbursement outcomes. Clinical expertise, industry leading advanced wound care products, and a strong understanding of reimbursement across all sites of service is the key for a successful practice,” said WoundGenex President and Co-founder, Thomas Smith.

 

“In partnering with WoundGenex, we are able to further substantiate our mission to increase access to innovative technologies for patients and customers alike,” said Rohit Kashyap, Ph.D., MIMEDX Chief Commercial Officer. “We are excited for the opportunity this program will provide to ensure more patients receive the care they need, as well as the opportunity to continue strengthening our reimbursement and service offerings for clinicians who choose our products.”

 

About WoundGenex
Founded in 2014 in Tampa, Florida, WoundGenex optimizes the way clinicians provide wound care to their patients in various places of service such as physician practices, hospitals, surgical centers, nursing homes, free-standing wound centers across the country. Thanks to more than two decades of experience in both the clinical and administrative aspects of wound care WoundGenex provides true solutions to help meet the challenges of providing best-in-class care from start to finish – from clinical and operational excellence to financial and procedural optimization.

 

To learn more about WoundGenex and the Premier Graft Purchasing Program, please visit https://woundgenex.com.

 

Media Inquiries: Media@WoundGenex.com

 

About MIMEDX
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit https://MIMEDX.com

 

MIMEDX Contacts

 

Investors:
Jack Howarth
Investor Relations
404.360.5681
jhowarth@mimedx.com

 

Media:
Hilary Dixon
Corporate & Strategic Communications
404.323.4779
hdixon@mimedx.com

 

Cision View original content:https://www.prnewswire.com/news-releases/woundgenex-partners-with-mimedx-to-launch-premier-graft-program-to-wound-care-providers-nationwide-301503626.html

 

SOURCE WoundGenex

by Teresa Carvalho MSc
The pivotal Phase 3 VIITAL clinical trial of EB-101, Abeona Therapeutics’ experimental cell therapy for wound healing in people with recessive dystrophic epidermolysis bullosa (RDEB), has met its enrollment target.

The company also announced that top-line results from the VIITAL trial (NCT04227106) are expected in the in third quarter of this year … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

New Orleans, LA
March 24 – March 27
Astor Crowne Plaza
Brochure

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

To understand the concepts of a wound and wound healing, we must examine the skin and its pathophysiology, as well as its unique structures and functions. Skin care and wound management must be grounded in a comprehensive knowledge base of the structure and functions of the skin. The skin is the largest organ of the body, covering approximately 18 square feet and weighing about 12 pounds, or up to 15% of total adult body weight. It requires one-third of an individual’s circulating blood volume to sustain it. Normal surface skin temperature is 92 degrees, compared with a core body temperature average of 98.6 degrees … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Manesh Patel MD, Christopher Granger MD and Larry Allen MD

 

One thing that you mentioned about risk factors is interesting, and I’m going to ask Larry, how do you usually think about comorbidities, including heart failure? I tell our fellows in clinic, if the patients don’t smoke and don’t have diabetes, those are overrepresented in PAD [peripheral artery disease]. This comes from data that are a bit older, but the PARTNERS study where they evaluated patients doing an ABI [ankle-brachial index] in primary care clinics, about 7000 patients, and they found that a quarter of them had PAD. If they were 50 years old and over, they tested whether they had diabetes and tobacco use, or over 70. Unrecognized PAD probably exists in about a quarter [of patients] in our primary care clinics, and it fits with these comorbidities … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Diabetic foot ulcers can be extremely challenging to treat and are associated with a high morbidity and mortality. A recent large randomised controlled trial (RCT), undertaken in the US, found that a single application of a fetal bovine acellular dermal matrix plus standard of care (SOC) is a faster and more effective treatment for these ulcers than SOC alone. This masterclass will explore this evidence base and debate how to optimise use of this dermal scaffold for this indication.

 

Wed, Mar 23, 2022 · 2:00 PM · EDT

 

John C. Lantis II
Chief of Surgery, Mount Sinai West Hospital

register

Michael S. Miller DO, • Lindsey Markey RN, BSN • Regina Yoder RN • Kevin Powers DPM• TCC Kits provided by M-Med

 

Introduction:
It is well stated in the literature that Total Contact Casting (TCC) is a standard of care for off-loading of neuropathic ulcers of the plantar surface. Another standard of care is to provide a moist wound healing environment. Evidence to support appropriate wound dressings under TCC is currently unavailable despite recognition that the wound environment and thus the amount of drainage changes as the wound progresses towards healing. This pilot case series of three patients with plantar based diabetic neuropathic ulcers uses two dressings, a five layer silicone foam with absorbent polymer and moisture retentive backing dressing (SF)* for low to moderate drainage and a non-adherent super-absorbent (SAP)† polymer dressing for moderate to high exudate levels.

 

Clinical Problem:
Many TCC kits include a generic, open-cell, polyurethane foam dressing (OCF). These dressings do not absorb or retain fluid in a moderate to high exudate environment which can lead to maceration and non-healing. Furthermore, due to the high moisture vapor transmission rate of OCF, wounds with low exudate may experience desiccation and result in the development of slough and biofilm.1

 

Methods:
This pilot case series evaluates the performance of two dressings under a TCC‡. The 1st dressing is a five-layer silicone foam with super-absorbent polymer and moisture retentive backing for low to moderately exuding wounds (SF)*. The 2nd dressing is a non-adherent absorbent (SAP)† polymer dressing for moderate to high exudate levels. A total of 3 Wounds were assessed, cleansed, debrided if necessary, categorized by exudate level, and TCC was applied for 7 days. The expected outcomes were to avoid maceration, increase in healthy granulation/epithelial tissue, and achieve maximum wear time of TCC.

 

Results:
All three of the pilot cases healed completely in acceptable time with no untoward complications. The important feature was that the changes in the amounts of drainage which were identified as the healing progressed were compensated for by changing the dressings based on the amounts of exudate identified. This effectively minimized associated peri-wound maceration, damage to the increasing granulation tissue and improved tolerance of their feet to the total contact casting.

 

Conclusion:
TCC kits should consider including dressings for low-moderate and moderate-high exudate and cease adding the one-dressing-fits-all generic foam into the kit. Additionally, although foam dressings are lumped into single category, their individual traits such at total volume handling, exudate retention, and MVTR have erratic variation in function. The SF in this case series exceeded expectation and can be a standard of care unless exudate overwhelms the dressing in the 7 day expected wear. At that time, SAP should be used in place of SF to manage high exudate. Our experience is that this combination of dressings progresses wounds towards healing, enhances the clinical benefits and wear time of TCC, and decreases the potential for wound healing complications.

 

Case History 1 45 year old Insulin-dependent diabetic male (IDDM) with a history of poor compliance presented with a plantar ulcer of 2 years duration. He had developed an acute Charcot’s Arthropathy, misdiagnosed as osteomyelitis and had surgery to remove “infected” bone. He had ongoing significant drainage with periwound skin maceration and no evidence of healing.	Course of Treatment: Aggressive debridement of the ulcer was performed with identified bone at the base of the ulcer. However, further workup did not demonstrate osteomyelitis. He was placed in a TCC and SAP used due to concerns about the excessive drainage. With the drainage controlled, maceration resolved and offloading successfully managed, he went on to heal completely.
Case History 2 64 year old IDDM with a history of a Diabetic Neuropathic foot ulcer of the plantar heel. He had undergone surgery years before leaving him with a soft tissue deformity predisposing him to recurrent ulcers.	Cource of Treatment An aggressive debridement was performed with no bone exposure noted. He had moderate serous drainage from the ulcer and so SF was used to control the drainage without creating a dry wound base. TCC was performed weekly with changes of the SF dressing. With the drainage controlled and offloading accomplished, he went on to heal completely.
Case History 3 A 64 year old female with advanced rheumatoid arthritis and foot deformity presented with a 6 month history of a nonhealing ulcer of the right plantar foot. A surgery to correct this had incisional dehiscence. Topical dressings and an offloading boot were previously used unsuccessfully.	Course of Treatment An aggressive debridement was performed with no bone exposure noted. Her significant serous drainage was treated with SAP and TCC applied weekly for offloading. Over the next several weeks, the drainage decreased and the dressing was changed to SF due to decreasing wound drainage. With the drainage controlled and offloading in place, she went on to heal completely.

References
1. Hurlow J, Couch K, Laforet K, Bolton L, Metcalf D, Bowler P. (2015) “Clinical Biofilms: A Challenging Frontier in Wound Care”. Adv Wound Care (New Rochelle) 4(5): 295–301.
* KerraFoam is a registered trademark of Crawford Woundcare Ltd. † KerraMax Care is a registered trademark of Crawford Woundcare Ltd.
‡ Total Contact Casting Kits by M-Med, Mebane, NC., supplied at no charge for this case series.
This poster abstract is funded and supported by Crawford Healthcare Inc.
© Copyright Crawford Healthcare Ltd, 2016. This literature and product report is supported and funded by Crawford Healthcare Ltd. 2016

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Researchers at the Royal College of Surgeons in Ireland (RCSI University of Medicine and Health Sciences, along with collaborators in Germany and Switzerland, say their work has revealed new information about how blood clots are formed during wound healing. Their study “Platelets drive fibronectin fibrillogenesis using integrin αIIbβ3”, which appears in Science Advances, examines the behavior of platelets at a wound site, specifically their ability to sense where within a blood clot they are and remodel their surroundings accordingly … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

A team led by Maria Leptin has shown in the fruit fly Drosophila that autophagy, a mechanism of stress responses in cells, plays an important role in wound healing: When a wound heals, the process of autophagy is initiated and regulated by the protein complex TORC1. This is a newly discovered function of autophagy and the first evidence that autophagy controls the formation of syncytia (multinucleated cells). While syncytia are also formed during the development of muscles or the placenta, their role in wound healing and the involvement of autophagy are new discoveries. The article, ‘Autophagy-mediated plasma membrane removal promotes the formation of epithelial syncytia’ has been published in The EMBO Journal … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

RedDress, a privately held U.S. and Israel-based wound care company, announced today it has been awarded a group purchasing agreement with Premier Inc. This agreement allows Premier members, at their discretion, access to RedDress’ wound care product, ActiGraft® system … ActiGraft is the first wound care product that enables health care providers to produce—in real time—an in vitro blood clot from a patient’s own blood. Once applied, the blood clot serves as a protective covering and supports the body’s natural wound healing response. ActiGraft can be used for a wide variety of hard-to-treat chronic wounds, including diabetic foot ulcers, pressure injuries, venous ulcers, traumatic wounds, and post-surgical wounds … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

of EB-101 in RDEBTopline data from VIITAL™ expected in the third quarter of 2022
Abeona Therapeutics (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that target enrollment has been achieved in its pivotal Phase 3 VIITAL™ study. The objective of VIITAL™ is to evaluate the safety and effectiveness of Abeona’s investigational EB-101 product for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of life. Large chronic wounds typically do not heal spontaneously and inflict the greatest pain and clinical burden on RDEB patients. Large chronic wounds treated in VIITAL™ measured greater than 20 cm2 of surface area and had remained open for more than six months. In a phase 1/2a study conducted at Stanford University, large chronic wounds treated with EB-101 showed considerable wound healing and reduction in associated long-term pain for up to six years … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

for Diabetic Foot Ulcer Infections
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,207,288 to Microbion on December 28, 2021, with claims to the use of Microbion’s proprietary pravibismane topical composition for diabetic foot infections (“DFI”). The patent, entitled “Bismuth-thiol compositions and methods for treating wounds,” extends topical pravibismane patent protection through to mid-2039. The granted claims cover the administration and use of topical pravibismane compositions in diabetic foot ulcer infections. This patent further expands Microbion’s patent portfolio, comprising granted claims to its pravibismane composition and methods of treating wounds and diabetic foot ulcers.

 

“We are pleased that the USPTO has granted this new patent supporting our pravibismane program for the treatment of diabetic foot infections,” said Dr. Brett Baker, Microbion’s President and Chief Innovation Officer. “This patent includes claims built on data from our Phase 1b clinical studies in infected patients. In these studies, topical pravibismane demonstrated a 3-fold reduction in chronic wound size compared to placebo when administered as an adjunct to standard of care treatment in patients with moderate to severe DFI. We are committed to developing novel therapies that fulfill the unmet needs caused by diabetic foot ulcer infections and faced by these patients every day.” … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

by Stephen “Andy” Rohrer, MSN, RN, APRN, AGACNP-BC, FNP-BC, CWS

I practice in West Memphis, Arkansas, about 15 miles from the city of Memphis, Tennessee. The location is suburban but the culture is rural. My people in Arkansas primarily work in farming and “blue collar” industries. West Memphis, Arkansas is separated from Memphis, Tennessee by the Mississippi River. We find that many Arkansans are simply intimidated by even the thought of crossing the bridge to go into Memphis (population about 650,000).

I am fiercely protective of my patients and our way of life here in Arkansas. I know they are hard-working, independent people who often try to fix things themselves; unfortunately, they show up for medical care only when things have progressed to dire circumstances. The drive time for patients to reach me varies from a few minutes to more than 2 hours. Our payer mix is increasingly Medicare Advantage plans … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Pain associated with chronic wounds can affect quality of life and have a major impact on physical, emotional and cognitive function. This module explores the importance of pain management, the mechanism and types of pain, as well as how to assess and manage pain.
Chronic wounds, Pain Management, Quality of life, Wound Care, Wound pain … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

New research led by the University of Bristol has found the protein p53 plays a key role in epithelial migration and tissue repair. The findings could improve our understanding of the processes used by cells to repair tissues, and be used to identify interventions that could accelerate and improve wound repair … Epithelial tissues are the linings that protect the body’s external skin and internal cavities, and their ability to repair themself is important. ?It is known that wounded epithelia repair themself thanks to the ability of the remaining cells to start migrating, collectively, to seal the breach. Specialised migratory cells called leader cells … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

WOUND CARE Q&A from Podiatry Today
Windy Cole, DPM, CWSP, Barbara Aung, DPM, DABPM, CWS, FAPWHc, Matthew Garoufalis, DPM, FASPS, FACPM, CWS, FFPM RCPS (Glasg), Brian Lepow, DPM, DABPM, and Eric J. Lullove, DPM, CWSP, DABLES, FAPWHc

 

Over the past several years, artificial intelligence (AI)-based innovation in the medical field has emerged, including in various types of imaging. How might such technology apply to the field of wound care? In this edition of the Wound Care Q & A column, the panelists share their experiences and thoughts on if AI could bring a new era of improved outcomes … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

18-19 May 2022 – Glasgow, UK
We believe that skin health and wound healing is everyone’s business and that change happens when we work together, not in silos.

We believe that skin health and wound healing is everyone’s business and that change happens when we work together, not in silos. Come to our annual face to face conference and you can join our community and listen to live lectures, interviews and discussions, take part in workshops, visit industry exhibition booths, network with colleagues and speakers and join the live conversations during the sessions.

Our conference really is space where professional connections are made, ideas are shared and collaborative action happens … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.
 

Cellular and/or tissue-based products (CTPs) comprise an exciting and emerging technology in wound care. Deep and large wounds require more than just a standard dressing, topical ointments, and time. Wounds that penetrate the reticular dermis and below (deeper than ~0.57 mm) require additional scaffolding to support wound closure and prevent significant scarring.1 CTPs provide this scaffolding as well as naturally occurring chemicals and cells that support wound healing … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.
 

March 16-19, 2022
Cedarbrook Lodge
St. Anne’s Hospital
Up to 18 CECH– Lectures (3/17-18)
Up to 8 CECH—Labs (3/19)
The 5th Annual Seattle Lower Extremity Surgery Symposium—SLESS offers continuing medical education on surgical techniques for lower extremity trauma and reconstruction. SLESS is a 3-day course, featuring two days of didactic lectures held at the Cedarbrook Lodge, 5 minutes from Seatac airport and one day of cadaveric skills sessions held at nearby St Anne’s Hospital 5 minutes’ drive from the hotel . Learn from a faculty of leading (MD and DPM) lower extremity surgeons … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.
 

Education for pressure ulcer assessment and prevention is essential to ensure that patients receive safe, effective, harm-free care. Aligning an effective care bundle with the best possible evidence-based practice helps to safeguard patients by reducing the risk of this classic avoidable harm.
Pressure area care … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.
 

It is estimated that one in four people with diabetes will have a diabetic foot ulcer during their lives, as a result of a combination of diabetes-related complications. Development of infection in a diabetic foot ulcer may be limb- or life-threatening. However, with good diabetes management and regular assessment this can be prevented … read more

Swift Medical, the global leader in digital wound care technology, is launching an innovative product that will revolutionize the future of healthcare … Today at 2pm EST / 11am PST, Swift Medical’s co-founder and CEO Carlo Perez will host a live broadcast from the TIFF Bell Lightbox in Toronto. At this event, Swift Medical will unveil a first-of-its-kind technology that will allow patients to access hospital quality care from anywhere and empower clinicians to prevent wounds before they even happen … Chronic wounds are one of the largest public health crises worldwide, with more than 8.2 million patients suffering from chronic wounds in North America alone. As rates of obesity, diabetes and other chronic conditions skyrocket, the number of patients at risk of developing chronic wounds will continue to rise … read more

Debridement is a key component of wound bed preparation for acute and chronic wounds because it helps to improve conditions at the wound bed to encourage healing. This, in turn, helps to reduce the risk of infection and improve patient quality of life.
Debridement … read more